Aura Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Aura Biosciences, Inc. (AURA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $4.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-11
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $1.70M, a 15.00% decline year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $2.60M, a 0.00% change year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $1.70M, a 19.05% decline year-over-year.
- Aura Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $2.00M, a 4.76% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month |
|---|---|---|---|
| 2026-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.30M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $2.60M 10-Q · filed 2026-05-11 | ||
| 2025-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.70M derived: sum of 2 quarters · filed 2026-08-11 | $6.30M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.60M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $2.60M 10-Q · filed 2026-05-11 | ||
| 2024-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.20M derived: sum of 2 quarters · filed 2025-11-13 | $6.40M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $4.30M 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $2.20M 10-Q · filed 2025-05-15 | ||
| 2023-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.60M derived: sum of 2 quarters · filed 2024-11-12 | $4.80M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.40M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $1.20M 10-Q · filed 2024-05-09 | ||
| 2022-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.50M derived: sum of 2 quarters · filed 2023-11-09 | $2.10M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.20M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $600.00K 10-Q · filed 2023-05-11 | ||
| 2021-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.00M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $500.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |